A phase 3, multicenter, open-label, randomized, comparatorcontrolled trial of the safety and efficacy of Dalbavancinversus Active Comparator in pediatric subjects with AcuteBacterial Skin and Skin Structure Infections
A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be Due to Gram-Positive Organisms
Dalbavancin for Pediatric Osteomyelitis
100 Clinical Results associated with Durata Therapeutics International BV
0 Patents (Medical) associated with Durata Therapeutics International BV
100 Deals associated with Durata Therapeutics International BV
100 Translational Medicine associated with Durata Therapeutics International BV